A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety, Efficacy and Pharmacokinetics of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Azilsartan (Primary)
- Indications Hypertension
- Focus Adverse reactions; Registrational
- Sponsors Takeda
- 18 Jun 2019 Status changed from active, no longer recruiting to completed.
- 30 Aug 2018 Planned End Date changed from 13 Aug 2019 to 11 Jun 2019.
- 30 Aug 2018 Planned primary completion date changed from 13 Aug 2019 to 11 Jun 2019.